Linezolid Kabi

Linezolid, the active ingredient in Linezolid Kabi, is an oxazolidinone presented as an injection solution for intravenous use. It treats complicated skin and soft tissue infections, community‑acquired and hospital‑acquired pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) in adult patients.

GNH USA supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable quality‑assured products for acute care and antimicrobial stewardship programs across the globe.

Linezolid is indicated for serious Gram‑positive bacterial infections, particularly those resistant to other antibiotics. - Complicated skin and soft tissue infections: provides effective therapy against MRSA and other susceptible Gram‑positive pathogens. - Community‑acquired and hospital‑acquired pneumonia: treats pneumonia caused by susceptible strains, including MRSA. - Infections caused by methicillin‑resistant Staphylococcus aureus (MRSA): offers targeted activity when alternative agents are limited. - Other serious Gram‑positive bacterial infections: used for bacteremia, endocarditis, osteomyelitis and similar infections caused by susceptible organisms.

Linezolid may cause a range of adverse reactions, varying from mild to severe, and clinicians should monitor patients accordingly. Common Side Effects: - Nausea: mild gastrointestinal upset that may be transient or persist during therapy. - Diarrhea: loose, watery stools that can lead to dehydration if severe. - Headache: transient cranial discomfort, often mild and responsive to analgesics. Serious or Rare Side Effects: - Thrombocytopenia: significant reduction in platelet count that may increase bleeding risk and require laboratory monitoring. - Peripheral neuropathy: nerve pain, tingling, or sensory loss that can be irreversible if not identified early. - Serotonin syndrome: potentially life‑threatening reaction characterized by agitation, hyperthermia, and autonomic instability when combined with serotonergic drugs.

Before initiating Linezolid therapy, several precautionary measures should be considered to ensure safe use. - Monitor blood counts: regular CBC testing to detect thrombocytopenia or anemia. - Assess renal function: dose adjustment may be needed in patients with impaired clearance. - Evaluate serotonergic medication use: avoid concomitant MAO inhibitors or SSRIs to prevent serotonin syndrome. - Use with caution in patients with a history of myelosuppression: increased risk of hematologic toxicity. - Check for hypersensitivity: discontinue if signs of allergic reaction such as rash or anaphylaxis appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid has notable drug interaction potential that clinicians must review before prescribing. Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use can precipitate serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): increase risk of serotonin toxicity. - Rifampin: induces hepatic enzymes, markedly reducing linezolid plasma concentrations. Moderate Interactions (Monitor Closely): - NSAIDs: may enhance bleeding risk when thrombocytopenia occurs. - Warfarin: linezolid can alter INR, requiring closer anticoagulation monitoring. - Oral contraceptives: may reduce hormonal efficacy, advising additional contraceptive measures.